The use of regorafenib in colorectal cancer
Colorectal cancer is the third most common type of cancer in men and the second in women worldwide. The data demonstrate the increase in the annual incidence of colorectal cancer, but still the significant number of patients is detected having late-stage cancer. Regorafenib is an oral multi-kinase i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2019-06-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/33513/pdf |
| _version_ | 1811288087209181184 |
|---|---|
| author | Marina I Sekacheva Nikolai N Bagmet Anastasia A Guryanova Diana Al' Rashi |
| author_facet | Marina I Sekacheva Nikolai N Bagmet Anastasia A Guryanova Diana Al' Rashi |
| author_sort | Marina I Sekacheva |
| collection | DOAJ |
| description | Colorectal cancer is the third most common type of cancer in men and the second in women worldwide. The data demonstrate the increase in the annual incidence of colorectal cancer, but still the significant number of patients is detected having late-stage cancer. Regorafenib is an oral multi-kinase inhibitor that targets kinases VEGF1, VEGF2, VEGF3, PDGFR, and FGFR involved in the regulation of tumor angiogenesis, and KIT, RET, RAF-1, BRAF involved in oncogenesis. The application of regorafenib has shown statistically significant increase of progression-free survival and overall survival, thus regorafenib been approved for the treatment of metastatic colorectal cancer, associated with resistance to fluoropyrimidine, oxaliplatin or irinotecan-based therapy in combination with the VEGR inhibitor and anti-EGFR-antibodies in patients with wild type KRAS gene. The article deals with the results of major studies carried out to explore the characteristics and efficacy and safety evaluation of regorafenib. We have analyzed in the review the results of recent studies on changes in indicators of overall survival, progression-free survival, and the efficacy of regorafenib therapy, safety and objective response. |
| first_indexed | 2024-04-13T03:29:47Z |
| format | Article |
| id | doaj.art-a36a46b8d6ac4fdc9178d69cd6459f87 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-04-13T03:29:47Z |
| publishDate | 2019-06-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-a36a46b8d6ac4fdc9178d69cd6459f872022-12-22T03:04:32ZrusIP Habib O.N.Современная онкология1815-14341815-14422019-06-01212333610.26442/18151434.2019.2.19041630243The use of regorafenib in colorectal cancerMarina I Sekacheva0Nikolai N Bagmet1Anastasia A Guryanova2Diana Al' Rashi3I.M. Sechenov First Moscow State Medical University (Sechenov University)B.V. Petrovsky Russian Scientific Center of SurgeryI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Colorectal cancer is the third most common type of cancer in men and the second in women worldwide. The data demonstrate the increase in the annual incidence of colorectal cancer, but still the significant number of patients is detected having late-stage cancer. Regorafenib is an oral multi-kinase inhibitor that targets kinases VEGF1, VEGF2, VEGF3, PDGFR, and FGFR involved in the regulation of tumor angiogenesis, and KIT, RET, RAF-1, BRAF involved in oncogenesis. The application of regorafenib has shown statistically significant increase of progression-free survival and overall survival, thus regorafenib been approved for the treatment of metastatic colorectal cancer, associated with resistance to fluoropyrimidine, oxaliplatin or irinotecan-based therapy in combination with the VEGR inhibitor and anti-EGFR-antibodies in patients with wild type KRAS gene. The article deals with the results of major studies carried out to explore the characteristics and efficacy and safety evaluation of regorafenib. We have analyzed in the review the results of recent studies on changes in indicators of overall survival, progression-free survival, and the efficacy of regorafenib therapy, safety and objective response.https://modernonco.orscience.ru/1815-1434/article/viewFile/33513/pdfregorafenibmetastatic colorectal cancer |
| spellingShingle | Marina I Sekacheva Nikolai N Bagmet Anastasia A Guryanova Diana Al' Rashi The use of regorafenib in colorectal cancer Современная онкология regorafenib metastatic colorectal cancer |
| title | The use of regorafenib in colorectal cancer |
| title_full | The use of regorafenib in colorectal cancer |
| title_fullStr | The use of regorafenib in colorectal cancer |
| title_full_unstemmed | The use of regorafenib in colorectal cancer |
| title_short | The use of regorafenib in colorectal cancer |
| title_sort | use of regorafenib in colorectal cancer |
| topic | regorafenib metastatic colorectal cancer |
| url | https://modernonco.orscience.ru/1815-1434/article/viewFile/33513/pdf |
| work_keys_str_mv | AT marinaisekacheva theuseofregorafenibincolorectalcancer AT nikolainbagmet theuseofregorafenibincolorectalcancer AT anastasiaaguryanova theuseofregorafenibincolorectalcancer AT dianaalrashi theuseofregorafenibincolorectalcancer AT marinaisekacheva useofregorafenibincolorectalcancer AT nikolainbagmet useofregorafenibincolorectalcancer AT anastasiaaguryanova useofregorafenibincolorectalcancer AT dianaalrashi useofregorafenibincolorectalcancer |